34 active not recruiting, 29 recruiting, 8 completed, 7 not yet recruiting. 51 Phase 2, 30 Phase 1, 18 Phase 3, 1 Phase 4.
Follow Ruxience: new trials by email Literature Review of Ruxience trials Research Report on Ruxience
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | City of Hope Medical Center | 58 | 2026-12-21 | 2026-10-22 |
| Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma, Gastric Mucosa-Associated Lymphoid Tissue Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 35 | 2026-12-16 | 2026-09-29 |
| Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients Biospecimen Collection, Computed Tomography, Cyclophosphamide - Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma | Phase 1 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 20 | 2026-12-08 | 2026-07-20 |
| Loncastuximab Tesirine and Rituximab as First-line Therapy in Patients With Post-transplant Lymphoproliferative Disorder (PLUTO) Loncastuximab tesirine, Rituximab or rituximab biosimilar - Post-transplant Lymphoproliferative Disorder | Phase 1 / Phase 2 | Not yet recruiting | University of Utah | 23 | 2026-11-01 | 2026-10-09 |
| Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma Biospecimen Collection, Cisplatin, Computed Tomography - Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma | Phase 1 | Not yet recruiting | National Cancer Institute (NCI) | 16 | 2026-10-30 | 2026-09-03 |
| Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Carboplatin - Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements | Phase 2 / Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 271 | 2026-10-30 | 2026-08-19 |
| Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma Rituximab, Tafasitamab, Biospecimen Collection - Classic Follicular Lymphoma, Grade 1 Follicular Lymphoma | Phase 2 | Recruiting | University of Washington | 30 | 2026-10-09 | 2026-10-15 |
| AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - AIDS-Related Diffuse Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 | Not yet recruiting | National Cancer Institute (NCI) | 15 | 2026-10-09 | 2026-08-13 |
| Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK Study Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Adult Burkitt Lymphoma | Phase 2 | Not yet recruiting | AIDS Malignancy Consortium | 43 | 2026-09-17 | 2026-10-16 |
| Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial Biospecimen Collection, Computed Tomography, Cyclophosphamide - Richter Syndrome, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 102 | 2026-08-04 | 2026-10-13 |
| Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Biopsy Procedure, Biospecimen Collection - Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified | Phase 2 | Recruiting | City of Hope Medical Center | 43 | 2026-07-27 | 2026-08-28 |
| Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 84 | 2026-05-29 | 2026-07-31 |
| Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Collection - B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia | Phase 2 | Suspended | University of Washington | 30 | 2026-05-08 | 2026-09-29 |
| Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study Acalabrutinib, Rituximab, Glofitamab - Phase 2 Study, MCL | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 30 | 2026-04-01 | 2026-05-20 |
| Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma Cyclophosphamide, Doxorubicin, Etoposide - B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1 | Phase 2 | Recruiting | University of Washington | 33 | 2026-03-30 | 2026-08-13 |
| Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma Venetoclax, Rituximab - Lymphoma, Marginal Zone Lymphoma | Phase 2 | Recruiting | Gottfried von Keudell, MD PhD | 33 | 2026-02-11 | 2026-03-13 |
| Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - B-Cell Non-Hodgkin Lymphoma, Burkitt Lymphoma | Phase 2 | Recruiting | University of Washington | 18 | 2025-12-07 | 2026-10-21 |
| Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration - B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Lymphoblastic Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 53 | 2025-10-10 | 2026-10-13 |
| Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Zanubrutinib, Rituximab, Obinutuzumab - Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | Phase 1 | Active not recruiting | University of Utah | 24 | 2025-09-12 | 2026-06-30 |
| Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cytarabine - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 2 | Recruiting | University of California, Davis | 25 | 2025-07-31 | 2026-06-30 |
Showing 20 of 85. Sign in to see all of them.
Lymphoma, Large B-Cell, Diffuse (14) · Leukemia, Lymphocytic, Chronic, B-Cell (12) · Burkitt Lymphoma (10) · Lymphoma, B-Cell (10) · Lymphoma, Mantle-Cell (10) · Lymphoma (9) · Lymphoma, B-Cell, Marginal Zone (9) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (6) · Lymphoma, Follicular (5) · Lymphoma, Non-Hodgkin (4) · Leukemia (3) · Hematologic Diseases (2) · Hodgkin Disease (2) · Leukemia, Biphenotypic, Acute (2) · Leukemia, Hairy Cell (2)
National Cancer Institute (NCI) (26) · M.D. Anderson Cancer Center (6) · University of Washington (6) · City of Hope Medical Center (5) · Academic and Community Cancer Research United (3) · Fate Therapeutics (3) · Mayo Clinic (3) · Children's Oncology Group (2) · Loxo Oncology, Inc. (2) · Sint Maartenskliniek (2) · University of California, Davis (2) · University of Utah (2) · AIDS Malignancy Consortium (1) · Amsterdam UMC, location VUmc (1) · BeOne Medicines (1)
United States (76) · Canada (8) · Australia (7) · Poland (5) · Brazil (4) · China (4) · Spain (4) · Belgium (3) · Bulgaria (3) · Czechia (3) · France (3) · Germany (3) · Hungary (3) · Israel (3) · Italy (3)
Catherine S Diefenbach (2) · Geoffrey Shouse (2) · Grzegorz S Nowakowski (2) · Joseph M Tuscano (2) · Mengyang Di, MD, PhD (2) · Aatke van der Maas (1) · Aatke van der Maas, MD PhD (1) · Alain Mina, M.D. (1) · Alex F Herrera (1) · Alexey V Danilov (1) · Alvaro J Alencar (1) · Ariela Noy (1)
PMID 35787017, PMID 39400109, PMID 27697771, PMID 28945884, PMID 29531316, PMID 29785709, PMID 30501481, PMID 30530801, PMID 30575311, PMID 31365801, PMID 32589970, PMID 33288485, PMID 33439748, PMID 34274940, PMID 34555839, PMID 34634256, PMID 34686472, PMID 34797699, PMID 34865212, PMID 35074072, PMID 35427411, PMID 36485104, PMID 36521030, PMID 37801678, PMID 38163318, PMID 38215395, PMID 39047240, PMID 39352751, PMID 39407334, PMID 39735417, PMID 39798981, PMID 40331908, PMID 40550489, PMID 40802906, PMID 41363770, PMID 41363773, PMID 41749915, PMID 42305039, PMID 42425121, PMID 42660130, PMID 42832396
U10CA180821 (7), P30CA033572 (5), U10CA180888 (5), U10CA031946 (4), U10CA180820 (4), P30CA015083 (3), U10CA021115 (3), U10CA180886 (3), U24CA196172 (3), UM1CA121947 (3), P30CA093373 (2), UM1CA186717 (2), 2015 (1), K23CA178183 (1), P30CA013330 (1)